Drugs / [18F] SPA-RQ
[18F] SPA-RQ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00088738 | Jul 2004 → Sep 2008 | panic disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F] SPA-RQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00088738 ↗ |
| Known as | \[18F\]-labeled Substance P Antagonist Receptor Quantifier | “In this protocol, we will use a new PET ligand that has demonstrated ability to serve as an NK1 receptor antagonist, \[18F\]SPA-RQ ( \[18F\]-labeled Substance P Antagonist...” NCT00088738 ↗ |
| Action | Inhibit | “NK1 receptor antagonist” NCT00088738 ↗ |
| Modality | Diagnostic / imaging agent | “new PET ligand” NCT00088738 ↗ |